title: Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
abstract: OBJECTIVE
  To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation.
  
  
  METHODS
  Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up.
  
  
  RESULTS
  Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day.
  
  
  CONCLUSIONS
  Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.
authors.affiliation: Department of Oncology, G Rummo Hospital, Benevento, Italy.
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.affiliation: Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.
authors.forename: Adina
authors.initials: A
authors.lastname: Croitoru
authors.affiliation: Department of Medical Oncology, University Hospital of Larissa, Larissa, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Papandreou
authors.affiliation: Department of Hepatogastroenterology, Centre Hospitalier Universitaire de Nancy, Université Henri Poincaré-Nancy, Vandoeuvre-lès-Nancy, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bronowicki
authors.affiliation: Services des Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Lille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Mathurin
authors.affiliation: Center of Gastroenterology, Liver Unit, Hospital de Santa Maria, Faculty of Medicine, Lisbon, Portugal.
authors.forename: Fatima
authors.initials: F
authors.lastname: Serejo
authors.affiliation: Department of Gastroenterology & Hepatology, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
authors.forename: Per
authors.initials: P
authors.lastname: Stål
authors.affiliation: Gastroenterology Department, Hospital de Montecelo, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Turnes
authors.affiliation: Service d'Hépato-Gastroentérologie, Université Pierre et Marie Curie and Hospital Pitié Salpêtrière, Paris, France.
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
authors.affiliation: Department of Oncology, St László Teaching Hospital, Budapest, Hungary.
authors.forename: György
authors.initials: G
authors.lastname: Bodoky
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000077157:Sorafenib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: GIDEON; dosing; safety; sorafenib; unresectable hepatocellular carcinoma